menu
    • menu

    Company profile for SiteOne Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of hypersensitivity disorders such as chronic cough, itch and pain. Our drug candidates are exquisitely selective inhibitors of voltage-gated sodium ion channels that are under investigation for the treatment of multiple neurogenic diseases by systemic and local routes of administration.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SiteOne TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    280 Utah Ave., Suite 250 South San Francisco, CA 94080
    Telephone
    Telephone
    +1 (406) 602-4558
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.siteonetherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/siteone-therapeutics-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly lands next-gen pain asset in $1B SiteOne acquisition
    Lilly lands next-gen pain asset in $1B SiteOne acquisition

    28 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-acquire-privately-held-siteone-2025-05-27/

    REUTERS
    28 May 2025
    Share Share
    SiteOne Announces Positive Ph 1 Data for STC-004 in Pain Treatment
    SiteOne Announces Positive Ph 1 Data for STC-004 in Pain Treatment

    04 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250204089126/en

    BUSINESSWIRE
    04 Feb 2025
    Share Share
    SiteOne Therapeutics Raises $100M for Non-Opioid Pain Treatments
    SiteOne Therapeutics Raises $100M for Non-Opioid Pain Treatments

    18 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241218587004/en

    BUSINESSWIRE
    18 Dec 2024
    Share Share
    SiteOne Therapeutics Awarded up to $15M Grant to Develop NaV1.8 Inhibitor
    SiteOne Therapeutics Awarded up to $15M Grant to Develop NaV1.8 Inhibitor

    18 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/siteone-therapeutics-awarded-up-to-15m-grant-to-develop-nav1-8-inhibitor-as-non-opioid-therapeutic-for-pain-301827642.html

    PR NEWSWIRE
    18 May 2023
    Share Share
    SiteOne Tx Collaborates with Vertex Pharma to Advance NaV1.7 Inhibitors for Pain
    SiteOne Tx Collaborates with Vertex Pharma to Advance NaV1.7 Inhibitors for Pain

    19 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/siteone-therapeutics-announces-collaboration-and-license-agreement-with-vertex-pharmaceuticals-to-advance-nav1-7-inhibitors-for-the-treatment-of-pain-301462776.html

    PRNEWSWIRE
    19 Jan 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search